Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab

BACKGROUND: BCD-021 is a bevacizumab biosimilar which was shown to be equivalent to reference bevacizumab in a wide panel of physicochemical studies as well as preclinical studies in vitro and in vivo. International multicenter phase III clinical trial was conducted to compare efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Stroyakovskiy, Daniil L., Fadeeva, Natalya V., Matrosova, Marina P., Shelepen, Konstantin G., Adamchuk, Grigoriy A., Roy, Bodhisatta, Nagarkar, Rajnish, Kalloli, Mahesh, Zhuravleva, Daria, Voevodin, Georgiy D., Shustova, Mariya S., Kryukov, Fedor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808992/
https://www.ncbi.nlm.nih.gov/pubmed/35105329
http://dx.doi.org/10.1186/s12885-022-09243-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808992/
https://www.ncbi.nlm.nih.gov/pubmed/35105329
http://dx.doi.org/10.1186/s12885-022-09243-7

Ejemplares similares